Millennium Management
IKT icon

Millennium Management’s Inhibikase Therapeutics IKT Stock Holding History

Millennium Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.92M Buy
2,928,077
+2,758,227
+1,624% +$4.9M ﹤0.01% 2965
2025
Q4 		$348K Buy
+169,850
New +$270K ﹤0.01% 5178
2025
Q2 		– Sell
-913,502
Closed -$2M – 6084
2025
Q1 		$2M Buy
913,502
+771,293
+542% +$1.94M ﹤0.01% 3785
2024
Q4 		$462K Buy
+142,209
New +$355K ﹤0.01% 4808
2022
Q4 		– Sell
-2,656
Closed -$14K – 6770
2022
Q3 		$14K Buy
+2,656
New +$14K ﹤0.01% 6561
2021
Q4 		– Sell
-16,880
Closed -$192K – 7071
2021
Q3 		$192K Buy
+16,880
New +$228K ﹤0.01% 6137
2021
Q2 		– Sell
-1,871
Closed -$67K – 6765
2021
Q1 		$67K Buy
+1,871
New +$75.7K ﹤0.01% 5746

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management's IKT Position: Q1 2026 in Review

Millennium Management increased its Inhibikase Therapeutics (IKT) stake by 1,624% in Q1 2026, buying an estimated $4.9M and bringing the position to 2,928,077 shares worth $4.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2965.

Millennium Management first reported a position in IKT in Q1 2021 and has held it in 7 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Millennium Management held 2,928,077 shares of Inhibikase Therapeutics worth $4.92M as of Q1 2026.
  • Millennium Management bought 2,758,227 Inhibikase Therapeutics shares in Q1 2026, an estimated $4.9M.
  • Inhibikase Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2965 holding.
  • Millennium Management first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.